Suggestions on the best timing of administration of capmatinib (Touradida) and treatment planning

Capmatinib (Capmatinib) is a highly selective MET inhibitor, mainly used to treat patients with METNSCLC) with n>exon14 skipping mutations (METex14). In clinical applications, rationally grasping the timing of medication and formulating scientific treatment plans are of great significance to drug efficacy and patient prognosis. Generally speaking, the best time to take capmatinib is when the patient is diagnosed with a positive MET mutation and the disease has entered an advanced stage or progressed. At this time, the drug can maximize its effect on inhibiting tumor signaling pathways.

At the diagnosis stage, patients usually need genetic testing to confirm whether there is a METex14 mutation. Once the test result is positive and the clinical stage meets the criteria for advanced or locally advanced lung cancer, capmatinib treatment can be considered as early as possible. Studies have shown that when medication is started at a stage when severe organ function damage has not yet occurred and the general condition is good, patients have a higher tumor remission rate and a more stable treatment response. In addition, capmatinib can also be an important option for later-line treatment for patients whose disease progresses after being ineffective or resistant to other treatments (such as chemotherapy and immunotherapy).

In terms of treatment planning, capmatinib is generally recommended to be taken orally continuously and regularly until the disease progresses or intolerable side effects occur. The treatment cycle does not have a fixed end time and is usually dynamically adjusted based on imaging evaluation (such as CT or PET-CT) and changes in clinical symptoms. For patients whose disease has achieved partial response or whose disease is stable, doctors often recommend maintenance therapy to extend progression-free survival (PFS). If mild to moderate adverse reactions occur during treatment, they can be controlled by adjusting the dose or briefly discontinuing the treatment, rather than directly terminating the course of treatment.

In addition, regular review throughout the course of medication is crucial. Patients usually need to undergo imaging evaluation every 8–12 weeks, and monitor liver and kidney function, blood routine, and other biochemical indicators to ensure the safety and effectiveness of treatment. Once the efficacy is found to be weakened or signs of resistance appear, doctors may consider combining other treatment strategies or changing targeted drugs. Therefore, the use of capmatinib is not just about taking the medicine on time, but also requires doctors to develop an individualized long-term treatment and monitoring plan to obtain the best clinical benefit.

Reference materials:https://www.drugs.com/